Abstract:
The aim of the study was to study in a comparative aspect some of the pharmacokinetics of Diclofenac sodium in
patients with rheumatoid arthritis with impaired gastric microbiocenosis (gastric dysbiosis) and without
disturbance (without dysbiosis). Material and methods: We examined 38 patients aged 18 to 60 years, with I-II-III
degree of disease activity. In addition to general clinical examination conductedenzyme immunoassay and urease
test to determine Helicobacter pylori andhigh performance liquid chromatography to determine the
pharmacokinetics of diclofenac. Results: studies and analysis of their results indicate that in conditions of
rheumatoid arthritis, in particular, in the presence of comorbid conditions, there is a decrease in the metabolic rate
and lengthening the half-life of NSAIDs, which increases the risk of side effects, especially from the
gastrointestinal tract and significantly affects the course of the disease and treatment results.
